提升PLK1通过触发BRD4酸化依赖的降解来克服前列腺癌中的BETi耐药性
Yanquan Zhang1, Ka-Wing Fong1, Fengyi Mao2
1Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Cell reports
|July 5, 2024
概括
含odomain的蛋白4 (BRD4) 通过PLK1依赖酸化在线分裂过程中被降解,这是前列腺癌治疗的关键机制. 这一发现有助于克服与多塞塔塞尔结合使用的BRD4抑制剂的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 含甲基蛋白4 (BRD4) 是前列腺癌 (PCa) 的治疗点.
- 了解BRD4稳定机制可以提高BRD4向治疗的疗效.
- 在细胞周期期间,BRD4蛋白水平波动,影响治疗反应.
研究的目的:
- 阐明调节在线分裂过程中的BRD4蛋白稳定性的机制.
- 研究波罗样酶1 (PLK1) 在BRD4降解中的作用.
- 探索结合化疗和BRD4抑制剂治疗前列腺癌的治疗策略.
主要方法:
- 在线转移过程中研究的BRD4蛋白水平.
- 使用了酸化位点映射和蛋白质降解试验.
- 采用基于细胞的测试来评估PLK1,CDK1/cyclin B和APC/CCdh1对BRD4的影响.
- 在PCa模型中测试了多塞和JQ1的顺序治疗.
主要成果:
- BRD4蛋白水平在线粒分裂过程中以PLK1依赖的方式显著下降.
- 在T1186处CDK1/环林B酸化物BRD4,在S24/S1100处招募PLK1进行进一步酸化.
- 酸化的BRD4被APC/CCdh1复合体识别,导致蛋白质体的降解.
- PLK1过度表达减少了SPOP突变稳定BRD4,使PCa细胞对BRD4抑制剂敏感.
- 连续使用多塞塔塞尔和JQ1治疗显著抑制了PCa的生长.
结论:
- 通过PLK1介导的BRD4酸化会在M阶段触发其降解.
- 这种降解途径对于调节前列腺癌细胞中的BRD4水平至关重要.
- 结合多塞塔克塞尔和JQ1,可以克服对原素和额外终端抑制剂 (BETi) 疗法的耐药性.
- 这些发现为开发前列腺癌新型治疗策略提供了见解.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


